Detailed Narrative
Specialty Chemicals Powers Profitability
The Specialty Chemicals segment remains the primary engine of growth, contributing 90% of the company's total EBITDA in Q1 FY26. Revenue grew 11% YoY, while EBITDA surged 52% to a record ₹130 crore, yielding a 27% margin. This performance was driven by robust demand in fine chemicals and CDMO businesses, with fine chemicals alone delivering over 15% YoY growth.
CDMO Pipeline and Agro Contract Execution
Management confirmed that the $300 million agro CDMO contract is on track for supply commencement in early 2026. The pharma CDMO funnel has doubled in size over the last few months, reflecting strong traction with innovators in the US, EU, and Japan. Additionally, the company has started deliveries for its first agro contract and is progressing on plant construction for a second one.
Strategic Pivot in Nutrition and Health
Despite a 4% YoY revenue decline in Nutrition due to lower Niacinamide pricing, the company is aggressively expanding into Human Nutrition. A dedicated team is scaling efforts in Choline Chloride and Choline Bitartrate. The imposition of a 125% anti-dumping duty on Chinese Choline Chloride in the EU is expected to significantly enhance Jubilant's competitive positioning in the European market.
Lean 2.0 and Operational Efficiency
The company is aggressively pursuing its Lean 2.0 cost-optimization program, targeting annualized savings of over ₹100 crore in FY26. These initiatives have already begun to bear fruit, particularly in the Chemical Intermediates segment, where EBITDA margins improved by 170 bps QoQ despite a volatile pricing environment. Management is also integrating Generative AI into R&D to accelerate product innovation.
Capex and Future Capacity Outlook
Jubilant Ingrevia plans to invest ₹600 crore in capex during FY26, primarily funded through internal accruals. Key projects include a new multi-purpose plant (MPP8) at Gajraula and a new boiler at Bharuch, which is 99% complete. Management expects the ₹2,000 crore total investment cycle to reach 70-80% utilization by the end of FY27, targeting a peak revenue potential of approximately ₹6,500 crore.